People with Medical Debt are Much More Likely to Experience Other Forms of Financial Stress February 12, 2024 News Release People with medical debt are much more likely than those without such debt to show other signs of financial vulnerability, like having no “rainy day” fund, overdrawing a checking account, or relying on costly loans, according to a new KFF analysis of national survey data. Medical debt remains a significant…
How Financially Vulnerable are People with Medical Debt? February 12, 2024 Issue Brief This analysis of government data finds that people with medical debt are much more likely to have other forms of financial distress than those without medical debt, like having no “rainy day” fund, overdrawing a checking account, or relying on costly loans.
The Burden of Medical Debt in the United States February 12, 2024 Issue Brief This analysis uses government data to examine the burden of medical debt, including variations based on state, age, race and ethnicity, and health status. It estimates that people in the United States owe at least $220 billion in medical debt.
3 Charts: Drug Prices in the United States February 7, 2024 News Release This post was updated to clarify that less than 10% of the nation’s total health spending is spent on retail prescription drugs and does not include spending on drugs administrated by physicians or in hospitals.Prescription drug costs are a top concern for the American public. While retail prescription drugs represent…
Commercialization of COVID-19 Vaccines, Treatments, and Tests: Implications for Access and Coverage February 6, 2024 Issue Brief With the depletion of the federal-purchased supply of COVID-19 vaccines, treatments and tests following the end of the public health emergency, this resource provides an overview of the implications of these changes for access to people covered by Medicare, Medicaid and private insurance, as well as those who are uninsured.
3 Charts: Medicare Drug Price Negotiations January 31, 2024 News Release Under the Inflation Reduction Act, the federal government for the first time will negotiate directly with drug companies to determine the prices that Medicare will pay for certain high expenditure drugs covered under Medicare Part D (starting in 2026) and Part B (starting in 2028). Part D covers retail prescription…
FAQs about the Inflation Reduction Act’s Medicare Drug Price Negotiation Program January 31, 2024 Issue Brief The Centers for Medicare & Medicaid Services (CMS) recently issued initial guidance describing CMS’s plans for implementation of the new Medicare Drug Price Negotiation Program, which was established by the Inflation Reduction Act. These FAQs address several questions related to Medicare’s drug price negotiation program and how CMS intends to implement the new program, with a focus on the details that apply for 2026, the first year that negotiated prices will be available under this new program.
Actual Tobacco Settlement Payments Received by the States (in millions) January 30, 2024 State Indicator